Akero Therapeutics: Q3 Earnings Insights
Portfolio Pulse from Benzinga Insights
Akero Therapeutics (NASDAQ:AKRO) reported Q3 earnings with an EPS of $-0.71, missing estimates by 4.41% compared to the expected $-0.68. Revenue remained unchanged from the same period last year. In the previous quarter, AKRO beat EPS estimates by $0.03, which led to a 6.59% share price increase the following day.
November 13, 2023 | 2:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Akero Therapeutics reported a Q3 EPS of $-0.71, missing the estimated $-0.68, with no change in year-over-year revenue. Previously, a positive earnings surprise resulted in a share price increase.
Missing earnings estimates typically leads to negative investor sentiment and can cause a short-term decline in stock price. However, the previous quarter's positive earnings surprise and subsequent share price increase suggest that market reactions can vary.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100